{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.5","upperLimit":"29.5","value":"23.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), DOR was defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. Duration of response per RECIST 1.1 by Blinded Independent Central Review (BICR) is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-clear cell Renal Cell Carcinoma (nccRCC) received 400 mg Pembrolizumab (Pembro) intravenously (IV) on Day 1 of a 42-day cycle (every 6 weeks (Q6W)) for approximately 2 years PLUS 20 mg Lenvatinib (Lenva) orally once daily (QD) on Days 1 and 22 of a 42-day cycle (Q6W). Participants continued study intervention until progressive disease or discontinuation.","id":"OG000","title":"Pembrolizumab + Lenvatinib"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study intervention and had confirmed complete response or partial response.","reportingStatus":"POSTED","timeFrame":"Up to approximately 47 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}